8-K filing — Pyxis Oncology, Inc. (PYXS)
Filed: 2026-10-01 AccNo: 0001437749-26-031767 Size: 828 KB Item 1.01: Entry into a Material Definitive Agreement Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Pyxis Oncology Analyst Flags Key Safety Liabilities from Cancer Drug
Pyxis Oncology shared Phase 1 trial data for MICVO in head and neck cancer, showing a 36% response rate alongside analyst safety concerns.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Pyxis Oncology shares are trading lower after the company announced the pricing of its $110 million offering of 36,047,919 shares at $2.90 with common warrants for 49,310,352 shares at a $3.50 exercise price.
Pyxis Oncology Prices $110M Offering Of 36,047,919 Shares At $2.90 With Common Warrants For 49,310,352 Shares At $3.50 Exercise Price
Pyxis Oncology Launches Public Offering Of Common Stock/Pre-Funded Warrants And Warrants To Fund MICVO Phase 3 Development; No Terms Disclosed